Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia.
via PubMed
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 399133414 | IUPAC_name = (2S)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide | image = Vestipitant structure.svg | image_class = skin-invert-image | width = 225
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).